The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients
Jens-Ulrik Jensen, Bettina Lundgren, Lars Hein, Thomas Mohr, Pernille L Petersen, Lasse H Andersen, Anne Øberg Lauritsen, Sine Hougaard, Teit Mantoni, Bonnie Bømler, Klaus Julius Thornberg, Katrin Thormar, Jesper Løken, Morten Steensen, Peder Carl, J Asger Petersen, Hamid Tousi, Peter Søe-Jensen, Morten Bestle, Søren HestadMads H Andersen, Paul Fjeldborg, Kim M Larsen, Charlotte Dahl Rossau, Carsten B Thomsen, Christian Ostergaard, J Kjaer, Jesper Grarup, Jens Lundgren
Dive into the research topics of 'The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients'. Together they form a unique fingerprint.